MEDI8897 is a monoclonal antibody that helps prevent lower respiratory tract illnesses caused by a virus that is the biggest cause of LRTI among infants and young children.

The agreement sees Sanofi Pasteur make an upfront payment of €120 million, plus a further payment of up to €495 million upon achievement of certain development and sales-related milestones. The companies will share all costs and profits equally and AstraZeneca will continue to lead all development activity.